European Vaccine Initiative

What European Vaccine Initiative does

European Vaccine Initiative (EVI) is a not-for-profit Product Development Partnership founded in 1998 and headquartered in Heidelberg, Germany. EVI catalyzes vaccine research and development for diseases of poverty and emerging infectious diseases by coordinating an ecosystem of more than 200 academic, industry, and public-health partners across five disease areas: malaria, leishmaniasis, diarrhoeal diseases, emerging epidemics, and antimicrobial resistance (AMR). The organization operates as an intermediary that bridges early-stage vaccine candidates from discovery to first-in-human clinical trials, with documented outputs including more than 40 vaccine formulations moved into clinical testing and more than 100 preclinical candidates supported by its services since inception.

EVI's product and service surface consists of research infrastructure platforms rather than commercial products. Core platforms include TRANSVAC (the European vaccine R&D infrastructure offering adjuvant and formulation services, mRNA vaccine development, in vivo infection models, immune monitoring, and preclinical production), ISIDORe II (a Horizon Europe-funded pandemic preparedness infrastructure), VACCELERATE (the pan-European vaccine clinical trial network), and the Inno4vac public-private partnership applying AI and computational modelling to vaccine R&D. Vaccine candidates coordinated by EVI include MV-NiV (measles-vector Nipah vaccine, first-in-human in 2026) and MV-ZIKA RSP (measles-vector Zika vaccine, completed Phase I). Supporting tools include GIADAMA and ADAMSEL software for malaria growth inhibition assays and ELISA data management. Implementation-research consortia MVPE-CC and OPT-MVAC generate evidence on malaria vaccine effectiveness across 14 African countries, feeding into WHO guidance.

The revenue model is grant-based: EVI receives restricted project funding from the European Union (Horizon Europe, Horizon 2020, FP7), IMI2 Joint Undertaking, EDCTP, GHIT Fund, CEPI, and individual donors, with major anchored commitments of €38.5M (Inno4vac, 2021–2027) and €10.5M (ISIDORe II). Services delivered through TRANSVAC are primarily free of charge, and additional revenue comes from donations through PayPal and bank transfer. Go-to-market is community-led and event-driven, depending on partnerships with academic institutions, other PDPs (DNDi, FIND, GARDP, IAVI, MMV, TB Alliance), research networks, and global health bodies rather than direct commercial sales channels.

Name

European Vaccine Initiative

Legal name

European Vaccine Initiative

Website

https://euvaccine.eu

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

European Vaccine Initiative (EVI) is a not-for-profit Product Development Partnership, founded in 1998 in Heidelberg, Germany, that coordinates vaccine R&D for diseases of poverty and emerging infectious diseases across 200+ global partners and five disease areas.

Ownership category

akta.pro rank

Product category

Vaccine Research and Development Services

NAICS

Medical and Diagnostic Laboratories (62151), Testing Laboratories and Services (541380)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Immunization & Vaccine Delivery Programs (BPADAIAB), Travel & Tropical Disease Vaccines (HLAIAEAE), Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Immunization & Vaccination Programs Administration (BPAIAJAD)

Keywords

• Vaccine research development
• Global health partnerships
• Clinical trial coordination
• Translational vaccine science
• Infectious disease vaccines

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Grant Funding and Donations: EVI operates as a not-for-profit Product Development Partnership (PDP) funded through grants from governments, foundations, and donors. The organization receives funding from entities such as the European Union (Horizon Europe, Horizon 2020, FP7), EDCTP, IMI2 JU, GHIT Fund, and individual donors. Revenue supports vaccine R&D activities rather than commercial product sales.
2. Service Delivery Contracts: EVI provides vaccine research and development services to the scientific community through TRANSVAC infrastructure, including adjuvant and formulation services, mRNA vaccine development support, preclinical production services. These services are often provided free of charge to researchers.
3. Donations: EVI accepts public donations to finance Research and Development activities contributing to new, effective and affordable vaccines for global health. Donation options include PayPal and direct bank transfer.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

European Vaccine Initiative (EVI) is a not-for-profit Product Development Partnership that coordinates vaccine research and development from early discovery through early-stage clinical trials, targeting diseases of poverty and emerging infectious diseases. EVI delivers this through three pillars: translational product development (bridging vaccine candidates to clinical testing), cross-cutting activities (harmonization, networking, and infrastructure access such as TRANSVAC), and knowledge sharing and advocacy. Services include vaccine adjuvant and formulation, mRNA development, in vivo infection models, immune monitoring, and preclinical production, provided to academic, public-sector, and industry partners worldwide.

Product overview

European Vaccine Initiative (EVI) is a not-for-profit Product Development Partnership that operates as a coordinating and service organization rather than a single product company. EVI's portfolio consists of multiple research infrastructure platforms and vaccine development initiatives: TRANSVAC provides R&D services including mRNA development and immune monitoring; ISIDORe II offers pandemic preparedness infrastructure; Inno4vac develops AI-powered predictive models for vaccine development; VAC2VAC created non-animal testing methods; and VACCELERATE coordinates pan-European vaccine trials. EVI also coordinates specific vaccine candidate programs including MV-NiV (Nipah), MV-ZIKA RSP (Zika), and placental malaria vaccines (VAC4PM), supported by software tools for data analysis (GIADAMA, ADAMSEL) and training programs for researchers from low- and middle-income countries.

Differentiator

Problem solved

Functional benefit

Products and services

• TRANSVAC European vaccine research infrastructure coordinated by EVI providing comprehensive vaccine R&D services including adjuvant and formulation services, mRNA vaccine development, in vivo infection models, immune monitoring services, and vaccine process development and preclinical production services. Delivered in collaboration with VFI, SSI, iBET, and HZI for the scientific community.
• ISIDORe II Integrated Services for Infectious Disease Outbreak Research II - pan-European pandemic preparedness infrastructure funded by Horizon Europe (€10.5 million budget over three years) providing coordinated access to high-containment facilities, advanced technologies, scientific expertise, biological resources, and data infrastructures for epidemic-prone pathogen research.
• Inno4vac IMI2-funded public-private partnership (€38.5 million, 2021-2027) developing advanced predictive models using AI for in silico vaccine immune response prediction, bio-manufacturing simulation, controlled human infection models, and 3D cell-based models to accelerate vaccine R&D timelines. Industry partners include GSK, Sanofi Pasteur, CureVac, and Takeda.
• VAC2VAC IMI2-funded project (2016-2022) dedicated to developing quality control testing approaches for human and veterinary vaccines using non-animal methods, validating in vitro assays including monocyte activation test and LC-MS/MS for batch consistency testing.
• VACCELERATE EU-wide vaccine clinical trial network funded by Horizon 2020, providing rapid response single entry-point for stakeholders from public health authorities to vaccine developers, enabling faster evaluation of experimental vaccinations and supporting more representative clinical trials.
• PrIMAVeRa IMI 2 JU funded project developing platform to assess how monoclonal antibodies and vaccines can reduce antibiotic use and resistance, focusing on antimicrobial resistance (AMR) pathogens like MRSA.
• MV-NiV Nipah Virus Vaccine Live attenuated measles vector vaccine expressing Nipah virus antigen, developed by researchers at The University of Tokyo. First-in-human Phase 1 trial successfully completed in Belgium in 2026, evaluating safety and immune response in 60 healthy adults. EVI served as sponsor representative for the trial.
• MV-ZIKA RSP Zika Vaccine Live attenuated recombinant measles-Zika vaccine candidate developed under the ZIKAVAX project. Phase I clinical trial conducted in Austria demonstrated safety and immunogenicity in healthy adults, with 24-month stability demonstrated.
• GIADAMA Software Tool Data analysis package for malaria parasite growth inhibition assays (GIA), developed to facilitate consistent and reproducible assay performance across laboratories.
• ADAMSEL Data Management System Auditable data management system for ELISA consisting of FPL application for converting OD readings to concentrations via four-parameter fitting and MERGE application for consolidating results.
• MVPE-CC Implementation Research Malaria Vaccine Pilot Evaluation-Case Control consortium conducting case-control studies in Ghana, Kenya and Malawi to assess RTS,S vaccine effectiveness under routine immunization conditions and compare four-dose versus three-dose schedules, generating evidence for WHO policy guidance.
• EDCTP/TDR Clinical Research and Development Fellowship Fellowship scheme providing training to junior to mid-career researchers from low- and middle-income countries to acquire specialist skills in clinical research and development through placements in pharmaceutical companies and Product Development Partnerships.

Quantifiable outcome

• Over 40 vaccine formulations moved into clinical testing since 1998
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

32 partnerships are on record, tiered core, minor and key.

• DNDicoreStrategic or Co-development Partner · 29 June 2026Drugs for Neglected Diseases initiative - co-author of EDCTP advocacy paper 'Advancing Global Health Innovation Through Europe-Africa Collaboration' with EVI and other Product Development Partnerships.
• FINDcoreStrategic or Co-development Partner · 29 June 2026Global alliance for diagnostics - co-author of EDCTP advocacy paper alongside EVI and other PDPs.
• GARDPcoreStrategic or Co-development Partner · 29 June 2026Global Antibiotic Research and Development Partnership - co-author of joint EDCTP advocacy paper with EVI and other Product Development Partnerships.
• IAVIcoreStrategic or Co-development Partner · 29 June 2026International AIDS Vaccine Initiative - co-author of joint advocacy paper for sustained EU investment in EDCTP under FP10.
• Medicines Development for Global HealthcoreStrategic or Co-development Partner · 29 June 2026Co-author of EDCTP advocacy paper alongside EVI and other Product Development Partnerships.
• MMVcoreStrategic or Co-development Partner · 29 June 2026Medicines for Malaria Venture - co-author of EDCTP advocacy paper with EVI and other PDPs.
• TB AlliancecoreStrategic or Co-development Partner · 29 June 2026Global partnership for TB drug development - co-author of EDCTP advocacy paper alongside EVI and other Product Development Partnerships.
• Guardian Global Health Resilience supplementminorGTM or Marketing Partner · 17 June 2026EVI contributed article to Guardian supplement on implementation research and health systems strengthening, authored by Dr. Irene Nkumama and Dr. Elena Ambrosio.
• MVPE-CC ConsortiumcoreStrategic or Co-development Partner · 17 June 2026Malaria Vaccine Pilot Evaluation-Case Control consortium conducting case-control studies across Kenya, Malawi, and Ghana generating evidence that informed WHO SAGE and MPAG guidance on RTS,S vaccine dosing schedule.
• OPT-MVAC ConsortiumcoreStrategic or Co-development Partner · 17 June 202614-country West and Central African consortium conducting locally-tailored implementation research at scale for malaria vaccination strategies.
• University of TokyocoreStrategic or Co-development Partner · 15 June 2026University of Tokyo researchers developed the MV-NiV Nipah virus vaccine (live attenuated measles vector expressing Nipah antigen) in 2013. EVI served as sponsor representative for the landmark first-in-human trial, bringing together international expertise and collaborative framework.
• Teikyo UniversitycoreStrategic or Co-development Partner · 15 June 2026Teikyo University served as sponsor of the first-in-human Nipah virus vaccine trial, with approval from Belgian authorities following GMP manufacture and proof-of-concept studies.
• Ghent University - CEVAC Immunomonitoring LabkeyStrategic or Co-development Partner · 15 June 2026Key partner providing immunomonitoring lab services for the Nipah virus vaccine trial, with dedication and scientific excellence instrumental in reaching the milestone.
• Harmony Clinical ResearchkeyStrategic or Co-development Partner · 15 June 2026Key partner whose dedication and scientific excellence were instrumental in the Nipah virus vaccine trial milestone.
• ERINHAcoreStrategic or Co-development Partner · 1 June 2026ERINHA coordinates ISIDORe II (Integrated Services for Infectious Disease Outbreak Research II) with €10.5M Horizon Europe funding over three years. EVI contributes TRANSVAC services through this framework.
• Vaccine Formulation Institute (VFI)keyStrategic or Co-development Partner · 1 June 2026TRANSVAC partner providing vaccine adjuvant and formulation services including access to mucosal and parenteral adjuvants and expertise in optimising vaccine formulations.
• Statens Serum Institut (SSI)keyStrategic or Co-development Partner · 1 June 2026TRANSVAC partner contributing to vaccine research and development services including immune monitoring and preclinical production capabilities.
• iBET - Instituto de Biologia Experimental e TecnológicakeyStrategic or Co-development Partner · 1 June 2026TRANSVAC partner from Portugal contributing to vaccine development services and infrastructure.
• Helmholtz Centre for Infection Research (HZI)keyStrategic or Co-development Partner · 1 June 2026TRANSVAC partner providing infection research expertise and capabilities for vaccine development.
• PrIMAVeRa ProjectkeyStrategic or Co-development Partner · 8 December 2025EU IMI 2 JU funded project developing platform to assess how monoclonal antibodies and vaccines can reduce antibiotic use and resistance, with focus on pathogens like MRSA.
• University of ColognekeyStrategic or Co-development Partner · 8 November 2025Lead coordinator of VACCELERATE pan-European vaccine trial network, working with EVI on clinical trial coordination and public outreach.
• NIBSC (National Institute for Biological Standards and Control)keyStrategic or Co-development Partner · 18 August 2022VAC2VAC project partner that will make monoclonal antibodies for DTaP ELISA and Luminex assays available to the public.
• CEPIcoreStrategic or Co-development Partner · 1 September 2021Coalition for Epidemic Preparedness Innovations partnered with EVI through TRANSVAC2 for vaccinology training collaboration via MoU signed in June 2021. CEPI's mission is to accelerate vaccine development against emerging infectious diseases.
• GSKkeyStrategic or Co-development Partner · 1 September 2021Industry partner in Inno4vac €38.5M IMI2 project. GSK collaborated on VAC2VAC project developing quality control testing approaches including monocyte activation test (MAT) for TBEV vaccine pyrogenicity testing.
• Sanofi PasteurkeyStrategic or Co-development Partner · 1 September 2021Industry partner in Inno4vac €38.5M IMI2 project focused on accelerating vaccine R&D timelines through predictive models.
• CureVackeyStrategic or Co-development Partner · 1 September 2021Industry partner in Inno4vac project contributing mRNA vaccine development expertise to the €38.5M public-private partnership.
• TakedakeyStrategic or Co-development Partner · 1 September 2021Industry partner in Inno4vac project bringing pharmaceutical expertise to the vaccine innovation partnership.
• Sclavo Vaccines AssociationkeyStrategic or Co-development Partner · 1 September 2021Italian association providing scientific coordination support for Inno4vac project alongside EVI as coordinator.
• Institut Pasteur PariskeyStrategic or Co-development Partner · 16 June 2021Partner in ZIKAVAX project developing Zika vaccine using measles vector platform, bringing unique technological expertise in viral vectors and vaccine development.
• Themis Bioscience GmbH (now MSD)keyStrategic or Co-development Partner · 16 June 2021ZIKAVAX partner with measles vector platform technology. Advanced MV-ZIKA RSP vaccine candidate through GMP manufacturing and Phase I clinical trial in Austria.
• CEA (Commissariat à l'énergie atomique et aux énergies alternatives)keyStrategic or Co-development Partner · 16 June 2021ZIKAVAX consortium partner bringing French scientific expertise in atomic energy and alternative energies to Zika vaccine development.
• ThinkYoungminorGTM or Marketing Partner · 28 April 2021Partnership with non-profit ThinkYoung to create inclusive framework for engaging young people in global health agenda and vaccination advocacy.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• FIND (Global Alliance for Diagnostics): Global non-profit accelerating diagnostic development for poverty-related diseases. Co-author of the EDCTP/FP10 advocacy paper with EVI; both share the PDP model and global health R&D funding dependencies, though FIND focuses on diagnostics.
• TB Alliance: Global non-profit PDP developing improved TB therapeutics. Part of the same eight-PDP EDCTP advocacy coalition with EVI and shares the Product Development Partnership model, donor base, and EU/global health R&D coordination role.
• Medicines Development for Global Health: Small Australian-based not-for-profit PDP developing medicines for neglected diseases. Co-author of EDCTP/FP10 advocacy with EVI; shares the small-PDP model, donor ecosystem, and EU funding dependencies.
• MMV (Medicines for Malaria Venture): Product Development Partnership for antimalarial therapeutics. Co-advocate with EVI in the EDCTP/FP10 paper; both organizations share malaria-endemic country implementation networks and global health funding dependencies.
• DNDi (Drugs for Neglected Diseases initiative): Not-for-profit PDP developing treatments for neglected diseases. Co-authored EDCTP/FP10 advocacy paper with EVI and shares the PDP coordination model, donor base, and global health R&D mission, though DNDi focuses on therapeutics rather than vaccines.
• CEPI (Coalition for Epidemic Preparedness Innovations): Larger global health PDP focused on accelerating vaccine development against epidemic threats. CEPI and EVI are direct collaborators (MoU via TRANSVAC2) and compete for similar EU/EDCTP/grant funding while serving overlapping academic and industry vaccine R&D networks.
• IAVI (International AIDS Vaccine Initiative): Non-profit PDP focused on vaccine development for HIV and other infectious diseases. IAVI shares EVI's PDP model, donor ecosystem, vaccine translational approach, and EDCTP advocacy coalition membership.
• GARDP (Global Antibiotic Research and Development Partnership): Non-profit PDP developing treatments for drug-resistant infections. EDCTP/FP10 co-advocate with EVI; shares the PDP model, donor base, and AMR/disease-of-poverty focus, though GARDP targets therapeutics rather than vaccines.

Broad incumbents

• Sabin Vaccine Institute: Global health non-profit advancing vaccine R&D and immunization advocacy. Operates in adjacent vaccine R&D and policy space, comparable to EVI in mission though with a broader US-based portfolio and different funding structure.
• PATH: Large global health non-profit with a Center for Vaccine Innovation and Access. PATH operates a broader portfolio (devices, diagnostics, advocacy) but its vaccine program directly overlaps with EVI's translational R&D and immunization implementation work.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/EuropeVaccine
• YouTubeyoutube.com/channel/UCWG8F6LPRTDoNffgAXmli1g/playlists
• LinkedInlinkedin.com/company/european-vaccine-initiative

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Vaccine Initiative